Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMNN-101

Vaccine (DNA plasmid) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Imunon

Phase 1/2 Most advanced trial (none active)

IMNN Developer

1 Registered trials

What is IMNN-101?

IMNN-101 is a DNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 spike antigen, formulated with a facilitating agent and aluminum phosphate adjuvant. It is being studied for COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (DNA plasmid)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Therapy area: Infectious disease
Developer: Imunon (IMNN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06283459	Phase 1/2	SARS CoV 2 Infection	Completed	IMNN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SARS CoV 2 Infection

More from Imunon

IMNN-001 Phase 3 Lyso-Thermosensitive Liposome Doxorubicin Phase 3

Sources

ClinicalTrials.gov NCT06283459

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMNN page.

Follow IMNN, the company behind IMNN-101

See IMNN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z